Drug Database
TE

tetracaine + lidocaine (Pliaglis / TetraPeel / Pliaglis)

✓ Approved

Sun Pharmaceutical Industries Ltd. · SCN9A · 小分子

什么是 tetracaine + lidocaine?

tetracaine + lidocaine 是一种小分子,由Sun Pharmaceutical Industries Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Pliaglis, TetraPeel, Pliaglis
公司Sun Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点SCN9A
给药途径Topical
状态Approved

作用机制

分子靶点

tetracaine + lidocaine 作用于 1 个分子靶点:

SCN9Asodium voltage-gated channel alpha subunit 9 (SFNP, GEFSP7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tetracaine + lidocaine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAnaesthesia✓ Approved
Nervous system disordersSensory loss✓ Approved

相关研究文献

PubMedClinical oral investigations2026-11-19

Intra-sulcular compound chamomile and lidocaine hydrochloride gel for procedural pain during ultrasonic scaling: a randomized, single-blind, split-mouth, sham-controlled superiority trial in adults with plaque-induced gingivitis.

Tang Rong R, Yin Tingting T, Liang Jia J, Wang Ruijie R et al.

This study aimed to evaluate whether intra-sulcular application of a compound chamomile and lidocaine hydrochloride gel (Kami-Gel) reduces procedural pain during ultrasonic supragingival scaling in adults with plaque-induced gingivitis compared with a sham procedure. A single-center, randomized, single-blind, split-mouth, sham-controlled superiority trial was conducted involving 114 adults with plaque-induced gingivitis. Participants received a sequential split-mouth treatment. The test side received intra-sulcular application of Kami-Gel, while the control side received a sham application (mimicked injection). The primary outcome was procedural pain intensity measured on a 0-10 Visual Analog Scale (VAS). Secondary outcomes included the number of pain complaints, procedural duration, patient satisfaction, and plaque index (PI). Safety was assessed immediately and at 24 h. All 114 participants completed the study. Median VAS score was significantly lower in the test group (1.7 [IQR: 0.62-2.58]) than the control group (4.1 [IQR: 2.42-5.7]), with an estimated treatment difference of - 2.35 (95% CI: -3.0 to - 1.7)-the upper limit of which fell below the pre-specified superiority margin of - 1.2, confirming superiority (P < 0.001). The test group also demonstrated significantly fewer pain complaints (median 0 vs. 1), shorter procedural duration (median 10 vs. 12 min), and higher patient satisfaction (all P < 0.001). Post-scaling plaque index was significantly lower in the test group (median 0.75 [IQR: 0.55-0.86] vs. 0.89 [IQR: 0.75-0.96]; P < 0.001), though this difference may reflect improved patient cooperation rather than a direct pharmacological effect. No adverse events were reported. Intra-sulcular application of compound chamomile and lidocaine hydrochloride gel reduces procedural pain during ultrasonic supragingival scaling compared to a sham procedure. Its use was associated with shorter active scaling time and higher satisfaction. Whether these acute benefits translate to improved long-term periodontal treatment compliance warrants further investigation. Intra-sulcular application of compound chamomile and lidocaine gel (Kami-Gel) prior to ultrasonic supragingival scaling reduces procedural pain and was associated with higher patient satisfaction. A lower post-scaling plaque index was observed in the test group, potentially attributable to improved patient cooperation during instrumentation. This safe, non-injectable chairside technique provides clinicians a practical tool to enhance patient comfort during scaling procedures.

PMID 43052462
阅读全文 →
PubMedFrontiers in medicine2026-11-18

Skin barrier impairment and topical local anesthetics: a review of percutaneous absorption and systemic toxicity risks.

Han Rui R, Zeng Jinmei J, Deng Zihao Z, Xia Lingyi L et al.

Topical local anesthetics are widely used in dermatologic surgery, laser therapy, and minimally invasive aesthetic procedures. In intact skin, the stratum corneum typically restricts the percutaneous absorption of local anesthetics; however, following skin barrier impairment due to inflammatory dermatoses, ulcers, burns, or post-laser and microneedling treatment, altered local permeation and systemic exposure profiles may affect their safety margin. This narrative review presents a structured synthesis of evidence pertaining to skin barrier dysfunction and the safety of topical local anesthetics. The article outlines the structure and barrier function of the stratum corneum and compares the characteristics of three types of impairment: inflammatory dermatoses, wound-related barrier loss, and iatrogenic barrier disruption. Using Fick's law of diffusion as a conceptual framework, it analyzes the core determinants of percutaneous absorption and compares the pharmacological profiles of commonly used agents, including lidocaine, prilocaine, tetracaine, and benzocaine. Available case evidence is synthesized, and the clinical presentation and differential diagnosis of systemic toxicity are summarized. A clinical risk stratification framework is proposed for patients with compromised skin barriers, and the potential and limitations of emerging strategies, including nanocarrier delivery, microneedle patches, and cryoanalgesia, are discussed. Existing evidence is predominantly derived from case reports, in vitro or animal studies, and small-scale clinical observations; pharmacokinetic data quantitatively relating the severity of barrier impairment to systemic exposure remain limited. Dosing regimens validated in intact skin should not be directly extrapolated to patients with barrier impairment. Future research should focus on developing pharmacokinetic prediction models integrating barrier injury type, administration parameters, and patient characteristics.

PMID 43048735
阅读全文 →
PubMedFrontiers in pharmacology2026-11-18

Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells.

Oostwouder Cees-Jan CJ, Vos Karin K, Merkus Mathijs R MR, Tolsma Casper S CS et al.

Local anesthetics are canonically used for analgesia and anti-arrhythmic therapy, but increasing evidence indicates additional anti-inflammatory properties, including modulation of purinergic signalling. A recent retrospective observational cohort study indicated that subcutaneous lidocaine-Hydroxypropyl-β-cyclodextrin (HP-β-CD) was associated with sustained improvements in quality of life in patients with neuropathic pain in post-COVID, but the underlying mechanism remains to be established. The aim of this study was to determine whether lidocaine and articaine, alone or in combination with HP-β-CD, modulate in vitro immune cell activation and cytokine secretion in human peripheral blood mononuclear cells (PBMCs). PBMCs were stimulated using phytohemagglutinin (PHA), lipopolysaccharide (LPS), or LPS combined with adenosine triphosphate (ATP) to engage P2X-associated inflammatory pathways, and compounds were applied both prior to and following stimulation. Cytokine secretion was quantified using a 13-plex immunoassay and cell activation was assessed by flow cytometry. Lidocaine-containing formulations attenuated cytokine secretion most prominently under conditions engaging ATP-dependent signaling, reducing interleukin-1β and interferon-α2, with interleukin-1β suppression being the most consistent effect across stimulation conditions. Articaine showed less consistent immunomodulatory effects than lidocaine, which may reflect its previously reported lack of purinergic receptor inhibition, while HP-β-CD alone did not influence immune activation or cytokine release under any condition. Together, these findings show that lidocaine-containing treatments can modulate cytokine responses in human PBMCs, particularly under LPS with ATP stimulation. These findings identify lidocaine as a modulator of ATP-dependent inflammatory signaling.

PMID 43047804
阅读全文 →
PubMedAdvanced healthcare materials2026-11-18

Bioadhesive Hyaluronic Acid-Cellulose Hydrogels for Sustained BDNF Release to Mitigate Local Anesthetic Neurotoxicity and Enhance Peripheral Nerve Repair.

Li Ziyou Z, Yin Wenming W, Qin Xinghui X, Bi Xinyu X et al.

Peripheral nerve block (PNB) is indispensable in regional anesthesia, yet local anesthetics such as lidocaine can provoke neurotoxicity, causing dorsal root ganglion injury and delayed nerve recovery. Although brain-derived neurotrophic factor (BDNF) is a potent neuroregenerative cue, its clinical value is limited by rapid degradation and poor local retention. Here, we report an injectable, bioadhesive hybrid covalent/dynamic hydrogel (DAHA-POMC) constructed from hyaluronic acid and cellulose for sustained BDNF delivery and peripheral nerve repair. The hydrogel exhibited rapid in situ gelation, favorable mechanics, elastic recovery, and controllable degradation, enabling prolonged retention of bioactive BDNF. In vitro, BDNF released from the DAHA-POMC hydrogel retained neurotrophic activity, and protected lidocaine-exposed dorsal root ganglion (DRG)-derived neuronal cells by improving viability, preserving mitochondrial membrane potential, reducing apoptosis, and promoting axonal outgrowth. Transcriptomic and protein analyses supported the involvement of ERK signaling in this neuroprotective effect. In vivo, in an intraneural lidocaine-associated sciatic nerve injury (SNI) model, the BDNF-loaded hydrogel significantly outperformed free BDNF, improving nerve conduction, remyelination, and gastrocnemius muscle preservation. Collectively, this work establishes DAHA-POMC as a multifunctional neuroregenerative platform that integrates localized BDNF delivery with regenerative tissue support, offering a potential post-injury treatment strategy for focal peripheral nerve injury associated with local-anesthetic exposure.

PMID 43045960
阅读全文 →
PubMedVestnik otorinolaringologii2026-11-18

[Possibilities of topical therapy of acute bullous otitis media].

Baranov K K KK, Vyazmenov E O EO, Kotova E N EN, Polunin M M MM et al.

Bullous myringitis is a borderline condition between inflammatory processes of the external and middle ear. The aim was to evaluate the comparative efficacy of three combined topical preparations in complex treatment of acute bullous otitis media. 140 patients aged 6-40 years (110 (78.6%) children) were divided into three groups: group 1 (n=50) - chloramphenicol+clotrimazole+beclomethasone dipropionate+lidocaine hydrochloride; group 2 (n=45) - phenazone+lidocaine; group 3 (n=45) - neomycin+polymyxin B+dexamethasone. Pain relief was fastest in group 2 (by day 3); otoscopic signs resolved by day 5, with the best combined results in group 1. In 25-28 (17.9-20.0%) patients bullous otitis was associated with PCR-confirmed influenza A (H1N1); Mycoplasma pneumoniae was detected in 4 (2.9%). The incidence peaked in December-February.

PMID 43046736
阅读全文 →
PubMedCureus2026-11-18

Blocking the Sympathetic Storm: Adjunctive Left Stellate Ganglion Block for Refractory Ventricular Tachycardia After Inferolateral Myocardial Infarction.

Goyal Mohit M, Razdan Shriya S, Ghosh Soumik S, Prajapati Rajpal R et al.

Electrical storm following myocardial infarction (MI) can be difficult to control when antiarrhythmic drugs and cardioversion fail. We describe a 53-year-old man with hypertension and previously undiagnosed diabetes who presented with an inferolateral ST-segment elevation MI caused by total occlusion of the proximal left circumflex artery, which was treated with primary percutaneous coronary intervention and drug-eluting stent placement. He then developed marked leukocytosis with a systemic inflammatory response and acute kidney injury (peak creatinine, 4.03 mg/dL), which resolved with empirical antibiotic therapy and supportive renal care. On day 6, he experienced recurrent syncope associated with sustained monomorphic ventricular tachycardia (VT) that persisted despite intravenous amiodarone and lidocaine, electrolyte correction, and repeated cardioversion, necessitating sedation and mechanical ventilation. Repeat coronary angiography demonstrated a patent stent. VT ceased following an ultrasound-guided left stellate ganglion block (SGB) using 1% lidocaine and dexamethasone, which resulted in Horner syndrome. Antiarrhythmic therapy was continued, and the patient was extubated within 24 hours. Speckle-tracking echocardiography demonstrated severely reduced lateral and anterior strain (global longitudinal strain, -12.0%). A patent stent in the culprit vessel and sustained monomorphic arrhythmia made a scar-related substrate the leading consideration. The close temporal association between the block and cessation of VT suggests that sympathetic blockade may have contributed to arrhythmia control, although the continuation of antiarrhythmic therapy precludes firm causal conclusions. Left SGB may serve as a rapid bridge to definitive treatment in patients with refractory electrical storm.

PMID 43048759
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tetracaine + lidocaine